Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Birmingham, Alabama

CNS medication trials in Birmingham, AL

26 CNS medication studies are recruiting participants at sites in Birmingham as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Birmingham at a glance

  • 26 studies are recruiting at a site in Birmingham.
  • By phase: Early Phase 1 (1), Phase 1 (1), Phase 1/2 (1), Phase 2 (5), Phase 2/3 (2), Phase 3 (12), Phase 4 (3), No phase (1). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (19), university, hospital or other (5), government (2).
  • By research area: Depression (8), Parkinson's Disease (6), Multiple Sclerosis (5), Migraine (3), Epilepsy (2), ADHD (1), Schizophrenia (1).
  • Most recent update to one of these records: November 17, 2026.

Depression studies recruiting in Birmingham

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    University of Alabama
    Registry record
    NCT07226661 · updated
  2. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study site
    UAB Psychiatry and Behavioral Neurology
    Registry record
    NCT06793397 · updated
  3. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    UAB, Psychiatry and Behavioral Neurology
    Registry record
    NCT07002034 · updated
  4. A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University of Alabama at Birmingham
    Registry record
    NCT07227454 · updated
  5. A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    University of Alabama at Birmingham - School of Medicine
    Registry record
    NCT07775300 · updated
  6. Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    Birmingham VA Medical Center, Birmingham, AL
    Registry record
    NCT07226232 · updated
  7. Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Syndeio Biosciences, Inc
    Study site
    University of Alabama at Birmingham
    Registry record
    NCT06547489 · updated
  8. Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Autobahn Therapeutics, Inc.
    Study site
    Autobahn Site #131
    Registry record
    NCT06633016 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Birmingham, AL on ClinicalTrials.gov.

Schizophrenia studies recruiting in Birmingham

  1. Biomarkers to Enhance Early Schizophrenia Treatment

    • Phase 4
    • Ages 18 to 35
    • All sexes
    Sponsor
    Northwell Health
    Study site
    The University of Alabama at Birmingham
    Registry record
    NCT06969755 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Birmingham, AL on ClinicalTrials.gov.

ADHD studies recruiting in Birmingham

  1. Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    Birmingham VA Medical Center, Birmingham, AL
    Registry record
    NCT05776056 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Birmingham, AL on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Birmingham

  1. A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Alabama- Birmingham ( Site 5015)
    Registry record
    NCT07216703 · updated
  2. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    University of Alabama at Birmingham
    Registry record
    NCT07174310 · updated
  3. A Study of Buntanetap in Participants With PD

    • Phase 2/3
    • Ages 40 to 85
    • All sexes
    Sponsor
    Annovis Bio Inc.
    Study site
    University of Alabama at Birmingham
    Registry record
    NCT07284784 · updated
  4. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    • Phase 2/3
    • Ages 40 to 80
    • All sexes
    Sponsor
    Biohaven Therapeutics Ltd.
    Registry record
    NCT06976268 · updated
  5. The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

    • Phase 1/2
    • Ages 30 and older
    • All sexes
    Sponsor
    University of Alabama at Birmingham
    Study site
    UAB Advanced Imaging Facility
    Registry record
    NCT03457493 · updated
  6. Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

    • Early Phase 1
    • Ages 18 to 99
    • All sexes
    Sponsor
    University of Alabama at Birmingham
    Registry record
    NCT06289582 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Birmingham, AL on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Birmingham

  1. A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Genentech, Inc.
    Study site
    Alabama Neurology Associates
    Registry record
    NCT07609719 · updated
  2. A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Celgene
    Study site
    Alabama Neurology Associates
    Registry record
    NCT06782490 · updated
  3. Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT05877963 · updated
  4. A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Alabama Neurology Associates PC
    Registry record
    NCT07225504 · updated
  5. Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

    • Phase 1
    • Ages 18 to 65
    • All sexes
    Sponsor
    University of Alabama at Birmingham
    Study site
    University of Alabama at Birmingham Medical Center
    Registry record
    NCT03759522 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Birmingham, AL on ClinicalTrials.gov.

Epilepsy studies recruiting in Birmingham

  1. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Registry record
    NCT07563881 · updated
  2. A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

    • Phase 3
    • Ages 2 and older
    • All sexes
    Sponsor
    Epygenix
    Study site
    University of Alabama at Birmingham
    Registry record
    NCT04462770 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Birmingham, AL on ClinicalTrials.gov.

Migraine studies recruiting in Birmingham

  1. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Central Research Associates, LLC (CRA) dba Flourish Research
    Registry record
    NCT07645924 · updated
  2. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Central Research Associates, LLC (CRA) dba Flourish Research
    Registry record
    NCT07674654 · updated
  3. Responding With Evidence and Access for Childhood Headaches

    • No phase
    • Ages 10 to 17
    • All sexes
    Sponsor
    Children's Hospital Medical Center, Cincinnati
    Study site
    University of Alabama at Birmingham Children's of Alabama
    Registry record
    NCT05889624 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Birmingham, AL on ClinicalTrials.gov.

Ask about studies near Birmingham

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call